Φορτώνει......
Progress and challenges for treating Type 1 diabetes
It has been more than 30 years since the initial trials of Cyclosporin A to treat patients with new onset Type 1 diabetes (T1D). Since that time, there have been insights into genetic predisposition to the disease, the failures of immune tolerance, and mechanisms that cause the immune mediated β cel...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Autoimmun |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4903889/ https://ncbi.nlm.nih.gov/pubmed/27210268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaut.2016.04.004 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|